Although cytomegaloviruses (CMVs) are species-specific, the study of nonhuman CMVs in animal models can help to inform and direct research aimed at developing a human CMV (HCMV) vaccine. Because the driving force behind the development of HCMV vaccines is to prevent congenital infection, the animal model in question must be one in which vertical transmission of virus occurs to the fetus. Fortunately, two such animal models-the rhesus macaque CMV and guinea pig CMV-are characterized by congenital infection. Hence, each model can be evaluated in "proof-of-concept" studies of preconception vaccination aimed at blocking transplacental transmission. This review focuses on similarities and differences in the respective model systems, and it discusses key insights from each model germane to the study of HCMV vaccines.
|Original language||English (US)|
|Journal||The Journal of infectious diseases|
|State||Published - Mar 5 2020|
Bibliographical notePublisher Copyright:
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: firstname.lastname@example.org.
- Congenital cytomegalovirus
- cytomegalovirus glycoproteins
- cytomegalovirus vaccines
- guinea pig cytomegalovirus
- rhesus macaque cytomegalovirus
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural